- Home
- ZENA vs MDXH Comparison
ZENA vs MDXH Comparison
Compare ZENA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENA
- MDXH
- Stock Information
- Founded
- ZENA 2017
- MDXH 2003
- Country
- ZENA Canada
- MDXH Belgium
- Employees
- ZENA N/A
- MDXH N/A
- Industry
- ZENA
- MDXH
- Sector
- ZENA
- MDXH
- Exchange
- ZENA NYSE
- MDXH Nasdaq
- Market Cap
- ZENA 99.2M
- MDXH 84.6M
- IPO Year
- ZENA N/A
- MDXH 2021
- Fundamental
- Price
- ZENA $5.90
- MDXH $2.44
- Analyst Decision
- ZENA Strong Buy
- MDXH Buy
- Analyst Count
- ZENA 1
- MDXH 1
- Target Price
- ZENA $9.00
- MDXH $6.00
- AVG Volume (30 Days)
- ZENA 1.9M
- MDXH 54.9K
- Earning Date
- ZENA 01-01-0001
- MDXH 08-20-2025
- Dividend Yield
- ZENA N/A
- MDXH N/A
- EPS Growth
- ZENA N/A
- MDXH N/A
- EPS
- ZENA N/A
- MDXH N/A
- Revenue
- ZENA $1,744,794.00
- MDXH $94,507,000.00
- Revenue This Year
- ZENA N/A
- MDXH $23.51
- Revenue Next Year
- ZENA N/A
- MDXH $17.68
- P/E Ratio
- ZENA N/A
- MDXH N/A
- Revenue Growth
- ZENA 24.50
- MDXH 25.46
- 52 Week Low
- ZENA $1.41
- MDXH $1.35
- 52 Week High
- ZENA $12.43
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- ZENA N/A
- MDXH 64.50
- Support Level
- ZENA N/A
- MDXH $2.17
- Resistance Level
- ZENA N/A
- MDXH $2.35
- Average True Range (ATR)
- ZENA 0.00
- MDXH 0.07
- MACD
- ZENA 0.00
- MDXH 0.01
- Stochastic Oscillator
- ZENA 0.00
- MDXH 96.90
About ZENA ZENATECH INC
ZenaTech Inc is a enterprise software technology company that specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The company operates in software development technology, sales, and distribution. The company is also developing a drone manufacturing, sales, and distribution business. It generates revenue from software licensing and subscription agreements, software support and maintenance, and technology consulting services.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.